MEET OUR PARTNERS AND SPONSORS
The Lipoprotein(a) Foundation is a patient-founded, 501(c)3 non-profit organization dedicated to preventing cardiovascular events due to high Lipoprotein(a) by diagnosing the most prevalent genetic risk for cardiovascular disease; educating and empowering patients and saving lives. We are fortunate to have such loyal and compassionate companies supporting our organization, and we thank them on behalf of the 1 in 5 people globally who have been affected by high Lipoprotein(a).
We do our utmost to develop strategic partnerships with companies who share our mission and values – saving lives by increasing awareness, advocating for routine testing, and supporting research that will lead to a specific treatment for high Lipoprotein(a). We invite you to make a difference by supporting our strategic objectives throughout the year. Sponsorship is a tremendous gift and demonstration of your commitment to the Lp(a) Community. Please contact email@example.com. Thank you.
2017 Disease Awareness Partners
Thank you to the following companies for their current pro bono services:
Wilson Sonsini Goodrich & Rosati is the premier legal advisor to technology, life sciences, and other growth enterprises worldwide. We represent companies at every stage of development, from entrepreneurial start-ups to multibillion-dollar global corporations, as well as the venture firms, private equity firms, and investment banks that finance and advise them. The firm's broad range of services and practice areas are focused on addressing the principal challenges faced by the management, boards of directors, shareholders, and in-house counsel of our clients.
Academic and Government Partners
The European Atherosclerosis Society (EAS) was founded in 1964 with the aim of “advancing and exchanging knowledge concerning the causes, natural history, treatment and prevention of atherosclerotic disease.” For more than 50 years the Society’s expertise has been used to teach clinicians how to manage lipid disorders and how to prevent atherosclerosis. By offering to our members access to educational materials, and opportunities to take part in Congress and courses, and by providing a forum in which new developments can be discussed, EAS contributes to the development of knowledge in the field, and ultimately to the improved treatment of persons with cardiovascular disease and lipid disorders.